Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer Full Text
Investigational New Drugs, 07/05/2012
Clinical Article
Manegold C et al. – With the highest dose of cilengitide (600 mg/m2), median progression–free survival (PFS) and 1–year survival were similar to those in patients treated with docetaxel 75 mg/m2 and there were fewer grade 3/4 treatment–related adverse events.



